To further explore the potential of ELFN1 as a target for cancer immunotherapy, we analyzed the OS of patients with high or low ELFN1 expression who received anti-PD1, anti-PDL1, or anti-CTLA4 therapy. The gene discussed is CTLA4; the disease is cancer.